Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Debt to Equity (2022 - 2025)

Historic Debt to Equity for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to $0.0.

  • bioAffinity Technologies' Debt to Equity fell 2939.68% to $0.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.0, marking a year-over-year decrease of 2939.68%. This contributed to the annual value of $0.01 for FY2024, which is N/A changed from last year.
  • bioAffinity Technologies' Debt to Equity amounted to $0.0 in Q3 2025, which was down 2939.68% from -$0.02 recorded in Q2 2025.
  • bioAffinity Technologies' Debt to Equity's 5-year high stood at $0.04 during Q3 2022, with a 5-year trough of -$0.02 in Q2 2025.
  • For the 4-year period, bioAffinity Technologies' Debt to Equity averaged around $0.01, with its median value being $0.01 (2024).
  • The largest annual percentage gain for bioAffinity Technologies' Debt to Equity in the last 5 years was 66345.59% (2025), contrasted with its biggest fall of 42440.14% (2025).
  • Quarter analysis of 4 years shows bioAffinity Technologies' Debt to Equity stood at $0.02 in 2022, then plummeted by 77.07% to $0.01 in 2023, then skyrocketed by 48.36% to $0.01 in 2024, then tumbled by 36.76% to $0.0 in 2025.
  • Its Debt to Equity stands at $0.0 for Q3 2025, versus -$0.02 for Q2 2025 and $0.03 for Q1 2025.